Combating antibiotic
resistance has found great interest in the
current clinical scenario.
Pseudomonas aeruginosa
, an opportunistic multidrug-resistant pathogen, is well known for
its deadly role in hospital-acquired infections. Infections by
P. aeruginosa
are among the toughest to treat because
of its intrinsic and acquired resistance to antibiotics. In this study,
we project gallium–curcumin nanoparticle (GaCurNP) conjugates
as a prospective candidate to fight against
P. aeruginosa
. The synthesized GaCurNPs were spherical with an average size ranging
from 25–35 nm. Analysis by Fourier transform infrared (FT-IR)
spectroscopy, Raman spectroscopy, and X-ray photoelectron spectroscopy
deduced the nature of interaction between gallium and curcumin. Conjugate
formation with gallium was found to improve the stability of curcumin
at the physiological pH. When tested after 24 h of contact, at the
physiological pH and 37 °C, the degradation of curcumin bound
in the GaCurNPs was 26%, while that of native curcumin was 95%. The
minimum inhibitory concentration (MIC) of GaCurNPs was found to be
82.75 μg/mL for
P. aeruginosa
(
ATCC
27853). GaCurNPs also showed excellent biofilm
inhibition at 4MIC concentration. Raman spectroscopic analysis showed
that GaCurNPs are capable of disrupting the cells of
P. aeruginosa
within 3 h of contact. Live/dead imaging
also confirmed the compromised membrane integrity in cells treated
with GaCurNPs. Scanning electron microscopy analysis showed membrane
lysis and cell structure damage. The AlamarBlue assay showed that
when L929 cell lines were treated with GaCurNPs with concentrations
as high as 350 μg/mL, the cell viability elicited by the nanoparticles
was 70.89%, indicating its noncytotoxic nature. In short, GaCurNPs
appear to be a promising antibacterial agent capable of fighting a
clinically significant pathogen,
P. aeruginosa
.